This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
… Chinese pharmaceuticalcompanies are developing domestic versions of “miracle” weight-loss drugs as they take on Western drugmakers selling anti-obesity medication in one of the world’s biggest markets , The Financial Times tells us. Meanwhile, do keep us in mind if you hear anything interesting.
Dr Eric Hughes joins Teva with experience in all phases of drug development at global pharmaceuticalcompanies, most recently Boston-based Vertex Pharmaceuticals, which he joined last year. He will be based out of Teva’s US headquarters in Parsippany, New Jersey. . Dr Hughes earned his MD and PhD at Yale School of Medicine.
This approach developed in collaboration between an academic researchlaboratory and a pharmaceuticalcompany is not just about lowering cholesterol—it’s about creating a new paradigm to design drugs that can prevent diseases by targeting proteins more cleverly.
” Tony Cundell: Contract manufacturing organisations (CROs), start-up companies, established pharmaceuticalcompanies and regulatory agencies are having difficulty recruiting and retaining technically-trained personnel. Dr Tony Cundell has a PhD in Microbiology from the Lincoln University, New Zealand.
We look forward to deepening our collaboration in next decades and contributing more to state-of-the-art clinical trials for efficient medicine to patients’ benefits throughout the world”, says XU Yi, CEO Teddy Clinical ResearchLaboratory. SZ) and Tigermed (300347.SZ SZ) and Tigermed (300347.SZ
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content